Loading
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Previous close
$23.48
−$0.86 · -3.53%
After-hours
$23.48
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Day range
Current $23.48
52-week range
Current $23.48
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
53
Mixed
Risk
45
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Day range
Current $23.48
52-week range
Current $23.48
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 89.06M USD | 65.44M USD | 45.23M USD | 25.92M USD |
| Cost of goods sold | 10.79M USD | 8.69M USD | 7.06M USD | 4.43M USD |
| Gross profit | 78.27M USD | 56.75M USD | 38.16M USD | 21.49M USD |
| Research and development | 19.14M USD | 13.56M USD | 9M USD | 7.24M USD |
| Selling, general, and administrative | 117.53M USD | 82.9M USD | 59.21M USD | 50.27M USD |
| Operating expenses | 136.68M USD | 96.46M USD | 68.2M USD | 57.51M USD |
| Interest expense | 1.89M USD | 1.99M USD | 2.1M USD | 1.6M USD |
| Depreciation and amortization | 1.34M USD | 1.14M USD | 847K USD | 497K USD |
| Operating income | −58.4M USD | −39.71M USD | −30.04M USD | −36.02M USD |
| Net income | −53.41M USD | −40.46M USD | −29.46M USD | −37.16M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$27.50
17.12% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI20.39M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM17.63M0.02%78.56B USD0.19%$277.7-1.29%
iShares Russell 2000 Growth ETFIWO6.22M0.04%14.25B USD0.24%$355.37-1.43%
Vanguard Extended Market ETFVXF6.01M0.01%95.4B USD0.05%$233.49-1.56%
Vanguard Russell 2000 ETFVTWO3.79M0.02%18B USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA3.17M0.01%22.01B USD0.03%$32.61-1.47%
iShares U.S. Medical Devices ETFIHI3.06M0.09%3.5B USD0.37%$50.95+0.04%
F/M Emerald Life Sciences Innovation ETFLFSC2.2M1.86%116M USD0.79%$41.8366-0.65%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIF/M Emerald Life Sciences Innovation ETFLFSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
